Literature DB >> 10066810

Phosphorylation of CD45 by casein kinase 2. Modulation of activity and mutational analysis.

Y Wang1, W Guo, L Liang, W J Esselman.   

Abstract

CD45 is a receptor-type protein-tyrosine phosphatase (PTP) that is required for antigen-specific stimulation and proliferation in lymphocytes. This study was designed to determine the nature of specific kinases in lymphocytes that phosphorylate CD45 and to determine the effect of phosphorylation on CD45 PTP activity. A major cytoplasmic lymphocyte kinase that phosphorylated CD45 was identified as casein kinase 2 (CK2) by use of an in-gel kinase assay in combination with immunoprecipitation, immunodepletion, and specific inhibition. Mutational analysis of CK2 consensus sites showed that the target for CK2 was in an acidic insert of 19 amino acids in the D2 domain, and Ser to Ala mutations at amino acids 965, 968, 969, and 973 abrogated CK2 phosphorylation of CD45. CK2 phosphorylation increased CD45 activity 3-fold toward phosphorylated myelin basic protein, and this increase was reversible by PP2A treatment. Mutation of Ser to Glu at the CK2 sites had the same effect as phosphorylation and also tripled the Vmax of CD45. CD45 isolated in vivo was highly phosphorylated and could not be phosphorylated by CK2 without prior dephosphorylation with phosphatase PP2A. We conclude that CK2 is a major lymphocyte kinase that is responsible for in vivo phosphorylation of CD45, and phosphorylation at specific CK2 sites regulates CD45 PTP activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066810     DOI: 10.1074/jbc.274.11.7454

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Preferential oxidation of the second phosphatase domain of receptor-like PTP-alpha revealed by an antibody against oxidized protein tyrosine phosphatases.

Authors:  Camilla Persson; Tobias Sjöblom; Arnoud Groen; Kai Kappert; Ulla Engström; Ulf Hellman; Carl-Henrik Heldin; Jeroen den Hertog; Arne Ostman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

Review 2.  CD45: all is not yet crystal clear.

Authors:  Nick Holmes
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

3.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

Review 4.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Authors:  Odile Filhol; Sofia Giacosa; Yann Wallez; Claude Cochet
Journal:  Cell Mol Life Sci       Date:  2015-05-20       Impact factor: 9.261

5.  Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase.

Authors:  Andrea Murányi; Justin A MacDonald; Jing Ti Deng; David P Wilson; Timothy A J Haystead; Michael P Walsh; Ferenc Erdodi; Eniko Kiss; Yue Wu; David J Hartshorne
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

6.  RPTPα phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.

Authors:  Yutao Wen; Shen Yang; Kuninobu Wakabayashi; Mattias N D Svensson; Stephanie M Stanford; Eugenio Santelli; Nunzio Bottini
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

7.  Serine/threonine phosphorylation of calmodulin modulates its interaction with the binding domains of target enzymes.

Authors:  E Leclerc; C Corti; H Schmid; S Vetter; P James; E Carafoli
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

Review 8.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45.

Authors:  Hyun-Joo Nam; Florence Poy; Haruo Saito; Christin A Frederick
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.